VAM
FOLD

Visium Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Visium Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-22,721
Closed -$247K – 1189
2015
Q1 		$247K Buy
22,721
+10,493
+86% +$92.5K ﹤0.01% 864
2014
Q4 		$102K Sell
12,228
-593,503
-98% -$4.07M ﹤0.01% 1000
2014
Q3 		$3.6M Buy
+605,731
New +$3.17M 0.05% 347

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Visium Asset Management's FOLD Position: Q2 2015 in Review

Visium Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2015, closing a stake of 22,721 shares — an estimated $247K sold.

Visium Asset Management first reported a position in FOLD in Q3 2014 and held it in 3 quarters. The position peaked at $3.6M in Q3 2014. 140 funds tracked by Wall St. Rank hold FOLD as of Q2 2015.

  • Visium Asset Management reported no remaining Amicus Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Visium Asset Management sold 22,721 Amicus Therapeutics shares in Q2 2015, an estimated $247K.
  • Visium Asset Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 3 quarters.
  • Visium Asset Management's Amicus Therapeutics position peaked at $3.6M in Q3 2014.
  • 140 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2015.

Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.